Affiliation:
1. From the Department of Cell Biology, New York University School of Medicine, New York, NY; and the Departments of Oncology and Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland.
Abstract
High serum concentrations of vascular endothelial growth factor (S-VEGF) and basic fibroblast growth factor (S-bFGF) are associated with unfavorable clinical characteristics in cancer. The combined effect of S-VEGF and S-bFGF on the survival of 200 patients with non-Hodgkin lymphoma (NHL) was studied. High S-VEGF and S-bFGF at diagnosis were associated with poor survival with the medians, the highest tertiles, or the highest quartiles as the cutoff values. The highest prognostic power was obtained when S-VEGF and S-bFGF were examined as a combination. Patients who had both S-VEGF and S-bFGF within the highest quartiles had only a 21% 5-year survival rate in contrast to a 64% 5-year survival rate among patients with both factors within the 3 lowest quartiles (P < .0001). Simultaneous elevation of S-VEGF and S-bFGF was associated with poor survival in different grades of lymphomas and in the largest histologic subgroup, the large-cell diffuse and immunoblastic lymphomas. S-VEGF (relative risk [RR], 1.83; P = .019) and S-bFGF (RR, 2.02; P = .0049) had independent influences on survival in multivariate models when tested together with the components of the International Prognostic Index (IPI). Patients with both S-VEGF and S-bFGF within the highest quartiles had nearly 3 times higher risk for death (RR, 2.90; 95% confidence interval [CI], 1.56-5.40;P = .0008) than the rest of the patients. This RR was higher than the relative risks associated with any of the components of the IPI in the same model. The authors conclude that the combination of S-VEGF and S-bFGF is a powerful prognostic variable in NHL.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference58 articles.
1. Angiogenesis in cancer, vascular, rheumatoid and other disease.;Folkman;Nat Med.,1995
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.;Hanahan;Cell.,1996
3. Angiogenesis: a dynamic balance of stimulators and inhibitors.;Iruela-Arispe;Thromb Haemost.,1997
4. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.;Dvorak;Am J Pathol.,1995
5. The biology of vascular endothelial growth factor.;Ferrara;Endocr Rev.,1997
Cited by
166 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献